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Conclusion: Patients smoking hand rolled cigarettes developing 
primary lung cancer have a smoking history of fewer cigarettes per day 
and less pack years tobacco consume than those smoking fabricated 
cigarettes, enhancing the opinion that hand rolled cigarettes are more 
carcinogenic. The use of hand rolled cigarettes among people develop-
ing lung cancer in Southern Norway is much higher than the average 
consume khown from ofﬁcial sales statistics.
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Objectives: In order to further characterize the difference of gender on 
the clinical, pathological status, survival and its predictive factors of 
patients on population-based lung cancer, and to determine time trends 
of gender differences, we analyzed the data which had been entered 
into Shanghai Cancer Registry System and executed by CDC. 
Methods: Data on demographics, stage at diagnosis, history and 
survival were obtained for all patients with primary bronchogenic 
carcinoma registered in Shanghai cancer registry system from 2002 to 
2004. The time trends of the male and female incidence in the urban 
population from 1972 to 2004 were assessed using APC (annual per-
cent change) analysis. Relative survival rates based on life-table analy-
sis methods were calculated to estimate the beneﬁt of cancer survival 
by compensating for the expected difference in baseline survival rates 
between male and female populations. Cox multi-variance analyses 
were used to evaluate prognostic factors; those factors were gender, 
age, residential area, pathological type, stage, and hospital grade. 
Results: 23196 new cases of lung cancer were diagnosed during 2002 
– 2004, the female crude incidence rate was 33.73/100000, and age-
adjusted rate was 30.90/100000. The male crude incidence rate and the 
age-adjusted rate were higher than those of female. The APC of male 
and female crude incidence continued to rise during the past 33 years 
(1.723% vs 2.036%, p <0.01). The male age-adjusted incidence rate 
in tendency to reduce was seen in the urban area (APC was -0.605%, 
p <0.01), but no change in female (APC was -0.136, p >0.05). There 
were more stage IV cases and adenocarcinoma in women than those 
of men (47.5% vs. 40.0%, 86.1% vs. 47.8%, respectively, p <0.05).
The overall 3-year survival rates and MST were signiﬁcantly higher 
in women than men (17.05% vs. 14.01% 0.83 year vs. 0.77 year, p < 
0.01). Stage-speciﬁc survival rates of women were also statistically 
higher than those of men for each stage (p < 0.05). The 3-year survival 
rates and MST were also signiﬁcantly higher in women adenocar-
cinoma than men (30.38%: 22.66%, 1.48 year: 0.98 year, p <0.01). 
Female gender was an independent positive prognostic factor (p < 0.01) 
by a multivariate Cox analysis, other positive prognostic factors were 
younger, urban area, squamous cancer, early stage, high-grade hospital. 
Conclusion: Shanghai is one of the high-incidence area of lung cancer 
in the world. The present study conﬁrms that women had statistically 
better outcomes than men in different stages of disease. The reasons 
behind these gender differences remain unclear. Exogenous or endog-
enous estrogens, gene, smoking, psychology, etc, may play roles to 
develop of the lung cancer in women.
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Background: Since 1997, lung cancer has become the leading cause 
of cancer deaths for both men and women in Taiwan. Gender-related 
differences in terms of histologic subtypes, stage at presentation, and 
survival rates have been reported but with conﬂicting ﬁndings. There 
is a growing global concern regarding cancer in women. With the 
introduction of new diagnostic and therapeutic modalities, this study 
was conducted to evaluate the trends of non-small cell lung cancer 
(NSCLC) between genders in recent years. 
Methods: A cohort of consecutive patients diagnosed with NSCLC at a 
180-bed referral cancer center in Taipei, who were clinically (including 
integrated positron emission tomography and computed tomography 
[PET/CT]) and pathologically staged by a surgeon and a pulmonologist 
experienced in video-assisted thoracoscopic surgery and trans-bron-
chial needle aspiration (TBNA) respectively, underwent homogenous 
treatment algorithms (i.e. new chemotherapeutic agents, target therapy, 
and 3D conformal radiotherapy) from January 2002 and followed-up 
until the end of 2006. Primary outcomes were the survival estimates 
derived by Kaplan-Meier analysis. 
Results: There were 738 patients (329 women and 409 men), who pre-
sented at a similar stage (p=0.95). The women were younger (mean age: 
58.4 vs. 62.2 year; p<0.001) and better overall age-adjusted and stage-
adjusted survival (p<0.001). Stage-speciﬁc survival favored women, 
with the differences becoming more signiﬁcant towards advanced stages 
(stage I disease, p=0.35; stage II, p=0.97; stage III, p=0.04; and stage 
IV, p<0.001). Among the 602 patients with unequivocal pathologic 
diagnosis, women were more likely to have adenocarcinoma (93.95%, 
p<0.001), which also comprised the majority (75.08%) in men. Patients 
with adenocarcinoma had better survival than those with squamous cell 
carcinoma (p=0.008). Pure bronchio-alveolar carcinoma (BAC) ac-
counted for 4.95% of adenocarcinoma and disproportionately occurred 
in women (72%). Survival was signiﬁcantly higher in patients with 
pure BAC histology than in those with adenocarcinoma other than BAC 
(p=0.02). In contrast with previous reports on recurrence patterns of 
BAC, an early and distinctly BAC hilar-mediastinal recurrence exclu-
sively in female patients was diagnosed by sequential serum carcino-
embryonic antigen follow-up and PET/CT-guided TBNA. 
Conclusions: There are gender-associated differences in the clinico-
pathologic characteristics and survival of NSCLC patients in the new 
era. The results can help guide pro-active government policies regard-
ing cancer and have the clinical importance for practicing clinician 
and/or researchers. Aggressive approaches to identify epidemiologic 
and biologic trends of lung cancer are needed at both the national and 
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individual institution level to improve prevention, screening, and treat-
ment efforts.
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Background: Cell cycle checkpoint function is crucial for the preven-
tion of carcinogenesis in mammalian cells. To test the hypothesis that 
common sequence variants of genes in the cell cycle control pathway 
may affect lung cancer predisposition, we explored the associations of 
11 polymorphisms in seven cell cycle control genes with lung cancer 
risk. 
Methods: We conducted a case-control study in Caucasians that in-
cluded 1,518 lung cancer patients and 1,518 controls. 
Results: Our results showed that when individuals with at least one 
variant allele were compared to homozygous wild-type carriers, a sig-
niﬁcantly increased lung cancer risk was identiﬁed for polymorphisms 
in p53 intron 6 (rs1625895) (odds ratio [OR] = 1.29, 95% conﬁdence 
interval [CI] 1.08-1.55) and in p27 5’ untranslated region (rs34330) 
(OR = 1.27, 95% CI 1.01-1.60). Compared with the homozygous 
wild-types, the homozygous variant F31I genotype (TT) of the STK15 
gene was associated with a signiﬁcantly reduced risk for lung cancer 
(OR=0.58, 95% CI = 0.37-0.90). The AA genotype of CCND1 G870A 
was associated with a signiﬁcantly increased risk (OR = 1.26, 95% 
CI 1.03-1.53) when compared with genotypes containing at least one 
wild-type allele. In an attempt to assess the combined inﬂuence of all 
the investigated polymorphisms on lung carcinogenesis, we found that 
compared to the reference group with one variant allele, individuals 
with two (OR = 1.53, 95% CI 0.97-2.41) and three or more (OR = 1.59, 
95% CI 1.07-2.34) variant alleles exhibited increasing risk of lung 
cancer with a gene dosage effect (P for trend = 0.041). This pattern was 
more evident in ever smokers (P for trend = 0.037), heavy smokers 
(P for trend = 0.020), and older subjects (P for trend = 0.011). Higher 
order gene-gene interactions were evaluated using the classiﬁcation and 
regression tree (CART) analysis, which indicated that STK15 F31I and 
p53 intron 6 polymorphism might be associated with lung carcinogen-
esis in never/light-smokers and heavy smokers, respectively. 
Conclusions: This is the ﬁrst study using a polygenic strategy to 
elucidate the inﬂuences of a panel of cell cycle genetic polymorphisms 
on lung cancer risk. Our results suggest that cell cycle gene polymor-
phisms and smoking may function collectively to modulate the risk of 
lung cancer.
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Background: RCTs on lung cancer treatment are increasing rapidly. 
Many meta-analyses were performed to synthesize and clarify their 
results. Even if the meta-analyses represent the high level of proof, 
their quality is variable. This review attempts to identify meta-analyses 
of RCTs studying lung cancer treatment, to assess their quality and to 
identify criteria of good quality. 
Methods: A systematic research was performed using PubMed, 
EMBASE, Cochrane, Web of knowledge, and American Society of 
Clinical Oncology databases, for 1990-2006, with the following search 
terms: lung cancer, meta-analysis and systematic review. There were no 
language restrictions. Meta-analyses of RCTs on lung cancer treatment 
published as full paper were eligible. Two investigators independently 
selected the publications. When the same results were reported in 
more than one publication, the evaluation was based on a combina-
tion of all available information. Data on meta-analysis characteristics 
(publication, size, methods…) were extracted by 2 investigators. After 
a learning period, each meta-analysis was evaluated independently by 
3 reviewers using the Oxman and Guyatt index and with the scoring 
method proposed by Sacks et al. Disagreements were resolved by dis-
cussion. The clinical relevance was evaluated by 2 clinicians. Quality 
criteria were identiﬁed by discriminant analysis through 3 groups of 
meta-analyses deﬁned by their quality score (poor, middle, high). We 
also compared the reports evaluating the same intervention.
Results: A total of 1,723 articles were retrieved by the initial search. 
Fifty-nine articles were considered to be eligible for assessment. Nine 
articles corresponded to update or duplicate papers of previous publica-
tions leading to 50 distinct projects. The 50 projects reported 70 meta-
analyses. 88% of reports were published in English. The articles were 
published between 1992 and 2006, 54% after 2003. 10% of articles 
were published by authors of the Cochrane Collaboration. The median 
numbers of trials and patients per project were 11 (3-57) and 2,094 
(360-11,160) respectively. 12.5% of meta-analyses were based on in-
dividual patient data. Among the 70 meta-analyses, 76% concerned the 
non-small cell lung cancer (NSCLC), 23% the small cell lung cancer 
(SCLC) and 1% lung cancer in general. 49 meta-analyses evaluated 
chemotherapy (7 in early NSCLC, 7 in locally advanced NSCLC, 16 
in advanced NSCLC, 14 in several stages of NSCLC and 5 in differ-
ent stages of SCLC), 12 radiotherapy (1 in early NSCLC, 2 in differ-
ent stages of NSCLC, 6 in limited SCLC and 3 in different stages of 
SCLC), 2 the association of chemotherapy and radiotherapy in locally 
advanced NSCLC, 1 surgery in early NSCLC and 6 other treatments 
(immunotherapy, Chinese herbs). For 11 therapeutic questions, more 
than 2 meta-analyses were performed. Analysis on quality evaluation is 
ongoing. 
Conclusion: A large number of meta-analyses of RCTs on lung cancer 
treatment had been published in the recent years, including several on 
the same topic. Their usefulness need to be studied. The assessment 
of the quality of meta-analyses and the comparison of reports on the 
same topic could permit to help clinicians and decision-makers in their 
practice. 
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Survey evidence from ex-smokers has repeatedly afﬁrmed that person-
alised concern about health consequences is the primary motivation 
